Total trials
205
Active
57
Phase 3
19
Total enrollment
53,288
Pipeline matrix
Showing 40 of 52 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Nivolumab | — | — | — | — | 3 | ||
| Cetuximab | — | — | — | — | 2 | ||
| 16 weeks of VEC + CDDP | — | — | — | — | — | 1 | |
| VEC + HD-MTX | — | — | — | — | — | 1 | |
| Chemotherapy + Valproate | — | — | — | — | — | 1 | |
| VEC | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Vesanoid | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Balstilimab | — | — | — | — | — | 1 | |
| Botensilimab | — | — | — | — | — | 1 | |
| Folfox Protocol | — | — | — | — | — | 1 | |
| XELOX | — | — | — | — | — | 1 | |
| HDM201 | — | — | — | — | 3 | ||
| Pazopanib | — | — | — | — | — | 3 | |
| Imatinib | — | — | — | — | — | 2 | |
| Temozolomide | — | — | — | — | 3 | ||
| Trametinib | — | — | — | — | 2 | ||
| Cabozantinib | — | — | — | — | — | 2 | |
| Pembrolizumab | — | — | — | — | 2 | ||
| NP137 | — | — | — | — | — | 2 | |
| Ribociclib | — | — | — | — | — | 1 | |
| Alectinib | — | — | — | — | — | 1 | |
| Regorafenib | — | — | — | — | — | 1 | |
| Dabrafenib | — | — | — | — | — | 1 | |
| Avapritinib | — | — | — | — | — | 1 | |
| Atezolizumab 1200 mg | — | — | — | — | — | 1 | |
| Imatinib 400 MG | — | — | — | — | — | 1 | |
| Tarlatamab | — | — | — | — | — | 1 | |
| Nilotinib | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 | |
| Sorafenib | — | — | — | — | — | 1 | |
| Lapatinib | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Durvalumab + Tremelimumab | — | — | — | — | — | 1 | |
| Dostarlimab | — | — | — | — | — | 1 | |
| Aromatase Inhibitors | — | — | — | — | — | 1 | |
| Treatment by regorafenib and best supportive care | — | — | — | — | — | 1 | |
| anti-PD-1/PD-L1 | — | — | — | — | — | 1 | |
| Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery | — | — | — | — | — | 1 |
12 more active programs hidden
Next readouts
- 2023-10-05
- 2024-12-15
- 2025-01
- 2025-07
- 2025-09-06
- 2026-01
- 2026-07-21
- 2026-10
- 2026-10-01
- 2026-12-30
Top conditions
- Breast Cancer17
- Colorectal Cancer10
- Cancer10
- Advanced Cancer6
- Metastatic Cancer6
- Sarcoma6
- Metastatic Renal Cell Carcinoma5
- Neoplasms4
Frequently asked questions about Centre Leon Berard
- How many clinical trials does Centre Leon Berard have on ClinicalTrials.gov?
- Centre Leon Berard is listed as the lead sponsor on 205 clinical trials in ClinicalTrials.gov, 57 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Leon Berard's trials are in Phase 3?
- 19 of Centre Leon Berard's trials are in Phase 3, spread across 52 active drug programs.
- What therapeutic areas does Centre Leon Berard focus on?
- Centre Leon Berard's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Colorectal Cancer, Cancer, Advanced Cancer, Metastatic Cancer.
- When are Centre Leon Berard's next clinical trial readouts?
- Centre Leon Berard has 10 upcoming primary-completion readouts tracked here; the soonest is “Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.”, expected around 2023-10-05.